» Articles » PMID: 12782051

A Review of the Effectiveness of Vaccine Potency Control Testing

Overview
Journal Int J Parasitol
Specialty Parasitology
Date 2003 Jun 5
PMID 12782051
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The use of potency control testing is a valuable tool for testing the actual relative strength of manufactured assembly lots of vaccine. Biological-based manufacturing methods are inherently variable and potency testing is a tool to ensure lot-to-lot consistency of commercial vaccines. A strong historical link to clinical efficacy has been established where correlation to efficacy and adequate test validation have been achieved. The link to immunogenicity and efficacy has traditionally been strongest with attenuated vaccines and toxoids. Control potency test failure does predict that a serial or batch of vaccine would most likely provide insufficient immunogenicity in typical field applications. Because of the complexity of pathogenic processes and associated immune responses, potency tests may not always directly predict the effectiveness of a vaccine. Thus, vaccines that pass control potency testing may not always provide adequate efficacy. This is particularly true of adjuvanted, inactivated vaccines. In the development of vaccine formulations and control tests for vaccines, the nature of the desired protective immune responses to the targeted pathogen (when known) should be considered. These considerations could provide better alternatives in the assays chosen as correlates of immunity and may more accurately predict efficacy and assure batch-to-batch consistency. Also, the effects of the dose and duration of antigen exposure as well as the nature of antigen presentation and generation of extrinsic cytokines could be characterised and correlated to vaccine potency as additional indicators of vaccine efficacy.

Citing Articles

Fully automated high-throughput immuno-µPlaque assay for live-attenuated tetravalent dengue vaccine development.

Wang Y, Troutman M, Hofmann C, Gonzalez A, Song L, Levin R Front Immunol. 2024; 15:1356600.

PMID: 38410513 PMC: 10895029. DOI: 10.3389/fimmu.2024.1356600.


Host genetic variation explains reduced protection of commercial vaccines against Piscirickettsia salmonis in Atlantic salmon.

Figueroa C, Veloso P, Espin L, Dixon B, Torrealba D, Elalfy I Sci Rep. 2020; 10(1):18252.

PMID: 33106499 PMC: 7588420. DOI: 10.1038/s41598-020-70847-9.


The importance of animal models in tuberculosis vaccine development.

Acosta A, Norazmi M, Hernandez-Pando R, Alvarez N, Borrero R, Infante J Malays J Med Sci. 2012; 18(4):5-12.

PMID: 22589668 PMC: 3328939.


Development and statistical validation of a guinea pig model for vaccine potency testing against Infectious Bovine Rhinothracheitis (IBR) virus.

Parreno V, Lopez M, Rodriguez D, Vena M, Izuel M, Filippi J Vaccine. 2010; 28(13):2539-49.

PMID: 20123054 PMC: 7115698. DOI: 10.1016/j.vaccine.2010.01.035.